Demonstration of bioequivalence is a critical requirement for gaining marketing authorization of new drugs and generics. These requirements are specified in the Code of Federal Regulations, Title 21, Part 320 (21 CFR Part 320) as they apply to dosage forms intended for oral administration. Substantial ...